Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...
University of Illinois Chicago scientists have redesigned a treatment for the most common pediatric leukemia to eliminate its severe side effects, like blood clots and liver damage. If approved, the ...
Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...
A targeted cancer therapy from AstraZeneca’s alliance with Daiichi Sankyo is now FDA approved to treat certain cases of advanced breast cancer, giving the British pharmaceutical giant another ...
The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer. The new indication applies to use of the agent by patients with HER2-low or HER2-utralow metastatic breast ...
The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer. The agent improved PFS but not OS vs. investigator’s choice of chemotherapy.
The approval emphasizes the importance of HER2 status testing in metastatic breast cancer to identify eligible patients for Enhertu treatment. The antibody drug conjugate was approved for patients ...
HER2-low or HER2-ultralow metastatic breast cancer following endocrine therapy.” Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate (ADC) developed using Daiichi Sankyo's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback